A vaccine supply agreement for low- and middle-income nations was terminated by Novavax.
In Japan, Shionogi received regulatory approval for its antiviral. Additionally, authorities in China are raising the alarm about an increase in instances.
For the most recent updates, please read below. You may read the daily COVID-19 tracker entries from April 14 to August 31 here.
As a result of Gavi's "material breach" of the contract, Novavax has terminated its supply arrangement for vaccines. The parties signed their agreement in May 2021, but according to Novavax, Gavi failed to purchase the 350 million doses of vaccine called for in the supply agreement. Doses were to be provided for low- and middle-income nations under the arrangement.
A domestic COVID-19 antiviral has received approval from Japan. The Wall Street Journal states that Shionogi is the company that created the medication, Xocova. The business also wants American approval.
As the number of cases in China continues to rise, officials in Beijing and Shanghai are stepping up their anti-pandemic efforts, according to Reuters.